Prezalumab - Amgen/AstraZeneca

Drug Profile

Prezalumab - Amgen/AstraZeneca

Alternative Names: AMG-557; B7RP-1 mAb; MEDI-5872

Latest Information Update: 21 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; MedImmune
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action B7-related protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sjogren's syndrome
  • Discontinued Cutaneous lupus erythematosus; Psoriasis; Systemic lupus erythematosus

Most Recent Events

  • 13 Aug 2018 MedImmune completes a phase II trial in Sjogren's syndrome in USA, United Kingdom, France and Sweden (SC) (NCT02334306) (EudraCT2014-003896-41)
  • 26 Jul 2018 Discontinued - Phase-I for Systemic lupus erythematosus in Taiwan, Germany, Denmark, Australia, United Kingdom, France, Malaysia, Canada and USA (SC)
  • 28 Apr 2018 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus in Australia (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top